Iovance Biotherapeutics (IOVA) Total Non-Current Liabilities (2017 - 2025)
Historic Total Non-Current Liabilities for Iovance Biotherapeutics (IOVA) over the last 8 years, with Q3 2025 value amounting to $76.9 million.
- Iovance Biotherapeutics' Total Non-Current Liabilities changed N/A to $76.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.9 million, marking a year-over-year change of. This contributed to the annual value of $77.7 million for FY2024, which is 907.39% down from last year.
- Per Iovance Biotherapeutics' latest filing, its Total Non-Current Liabilities stood at $76.9 million for Q3 2025.
- In the past 5 years, Iovance Biotherapeutics' Total Non-Current Liabilities ranged from a high of $106.6 million in Q1 2024 and a low of $70.6 million during Q1 2023
- For the 3-year period, Iovance Biotherapeutics' Total Non-Current Liabilities averaged around $83.4 million, with its median value being $79.8 million (2025).
- Its Total Non-Current Liabilities has fluctuated over the past 5 years, first soared by 5095.45% in 2024, then tumbled by 2852.93% in 2025.
- Iovance Biotherapeutics' Total Non-Current Liabilities (Quarter) stood at $85.4 million in 2023, then dropped by 9.07% to $77.7 million in 2024, then decreased by 1.04% to $76.9 million in 2025.
- Its Total Non-Current Liabilities stands at $76.9 million for Q3 2025, versus $79.8 million for Q2 2025 and $76.2 million for Q1 2025.